ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the "Existing Warrants") at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares. In consideration for the immediate exercise of the warrants for c
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (NASDAQ:VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Our Company recently announced positive results of the phase 1b/2 study of its lead product, pepinemab, in early stages of Alzheimer's disease (AD). The purpose of this report is to share additional data related to cognitive effects that may help clarify the goals of this study, how well it succeeded, and how this success supports continued development of pepinemab in AD and other neurodegenerative diseases including Huntington's Disease (HD), which was the focus of a larger previously
Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington's disease based on similarities to neuroimmune pathology in Alzheimer's ROCHESTER, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering treatment of Alzheimer's disease (AD) with anti-Semaphorin 4D (SEMA4D) antibody, today announced positive results of its early stage SIGNAL-AD clinical trial of pepinemab antibody in AD. Topline results were presented by Eric Siemers, MD, Principal Investigator of
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Alzheimer's Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session.
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
8-K - VACCINEX, INC. (0001205922) (Filer)
8-K - VACCINEX, INC. (0001205922) (Filer)
10-Q - VACCINEX, INC. (0001205922) (Filer)